HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation
Journal of the American Heart Association · 07.07.2026 · 15 (13)
DOI: 10.1161/jaha.125.046773 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 07.07.2026. Verfasst von Hongmei Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Site of Peking University People's Hospital Beijing China. Hauptthemen laut MEDLINE: Myocardial Ischemia, Heterogeneous-Nuclear Ribonucleoprotein Group C. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Several studies have suggested that N6‐methyladenosine (m6A) plays an essential role in cardiovascular disease, but the causality of m6A on ischemic heart disease (IHD) remains unknown. Therefore, this study investigated the potential relationship between m6A and IHD using a 2‐sample Mendelian randomization method.
Methods
The publicly available genome‐wide association study data for m6A‐related proteins were obtained from the INTERVAL study, a large population‐based cohort of healthy blood donors in the United Kingdom, whereas the genome‐wide association study database (including 30 952 cases and 187 840 healthy controls) provided the IHD data. We performed a 2‐sample Mendelian randomization analysis to evaluate the potential causal association between HNRNPC (heterogeneous nuclear ribonucleoprotein C) and IHD, followed by experimental validation in vitro and in vivo to confirm the role of HNRNPC in IHD pathogenesis.
Results
There was no indication of pleiotropy or heterogeneity among the 6 m6A‐associated proteins, but Mendelian randomization analysis revealed that HNRNPC (odds ratio [OR], 0.93 [95% CI, 0.88–0.97]; P =0.002) was associated with IHD. When IHD developed, there was a significant upregulation of HNRNPC expression in both animal and cellular tests. HNRNPC knockdown prevented oxidative stress, mitochondrial dysfunction, and cell death.
Conclusions
The Mendelian randomization study suggests a potential causal association of the m6A‐related protein HNRNPC in the cause of IHD and verified the accuracy of the results through a series of experiments, which will help us understand the pathogenesis of IHD and identify potential therapeutic targets in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Site of Peking University People's Hospital Beijing China.
- Department of Pharmacy Peking University People's Hospital Beijing China.
- School of Life Clinical Pharmacy Shenyang Pharmaceutical University Shenyang China.
ORCID-Profile: Hongmei Ye, Xinyu Wang, Xuchen Song, Jing Guo
Zitieren
APA
Ye, H., Wang, X., Meng, S., Song, X., He, X., Huang, L., Zhang, X., & Guo, J. (2026). HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation. Journal of the American Heart Association, 15(13). https://doi.org/10.1161/jaha.125.046773
Vancouver
Ye H, Wang X, Meng S, Song X, He X, Huang L, et al. HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation. Journal of the American Heart Association. 2026;15(13). doi:10.1161/jaha.125.046773
BibTeX
@article{Ye2026,
author = {Ye, Hongmei and Wang, Xinyu and Meng, Siyu and Song, Xuchen and He, Xu and Huang, Lin and Zhang, Xiaohong and Guo, Jing},
title = {HNRNPC as a Novel Therapeutic Target for Ischemic Heart Disease: Evidence From Mendelian Randomization and Experimental Validation},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {13},
doi = {10.1161/jaha.125.046773}
}
EUVIMED